羟基喜树碱为主的联合化疗结合同期放射治疗晚期非小细胞肺癌

目的：探讨羟基喜树碱联合顺铂和氟尿嘧啶结合同期放疗治疗晚期非小细胞肺癌的临床疗效和毒性反应。方法：羟基喜树碱6mg/m^2，静脉滴注第1～5天，顺铂30mg/m^2，静脉滴注第1～3天，氟尿嘧啶300mg/m^2，静脉滴注第1～5天，28天为一个周期，至少治疗2周期。放射治疗与化疗同期进行，原发灶总剂量DT50～70Gy／25～35次／5～9周，转移病灶30～60Gy/10～30次／2～8周。结果:全组共31例，完全缓解(CR)6例，部分缓解(PR)18例，总有效率为77．4％。中位生存期16．7个月，1、2年生存率分别为54．7％、30．2％，1、2年局部控制率分别为61％、40％。主要毒副反应是骨髓抑制和消化道反应，但均可耐受。结论:羟基喜树碱为主的联合化疗结合同期放疗是治疗晚期非小细胞肺癌的有效方法，能减轻症状，改善生存质量，延长生存期。

Hydroxycamptothecin-based chemotherapy combined with concurrent radiotherapy for advanced non-small cell lung cancer

Objective To evaluate the effects and toxicities of combination therapy of chemotherapy with hydroxycamptothecin (HCPT)+5 fluorouracil (5 FU)+cisplatin (DDP) and concurrent radiotherapy for advanced non small cell lung cancer (NSCLC). Methods From September 1999 to May 2001, 31 patients with advanced NSCLC were enrolled in this study. They were given chemotherapy with HCPT 6 mg/m 2 on days 1 5, 5 FU 300 mg/m 2 on days 1 5, DDP 30 mg/m 2 on days 1 3 and concurrent radiotherapy. The chemotherapy was repeated every 28 days as a cycle. Each patient should receive at least two cycles. The total dose of primary tumors varied up to DT 50 70 Gy/25 35 f, and that of metastatic tumors up to DT 30 60 Gy/10 30 f . Results Among the 31 patients, 6 got complete response, 18 got partial response, 5 had stable disease and 2 had progressive disease, with an overall response rate of 77.4% (24/31). The median survival duration was 16.7 months. The 1 and 2 year survival rates were 54.7% and 30.2%, and 1 and 2 year local control rates were 61% and 40%, respectively. The main toxicities were marrow suppression and gastrointestinal symptoms. Conclusion The results suggest that HCPT based chemotherapy combined with concurrent radiotherapy is effective for NSCLC and can improve the survival rate and life quality of the patients with lung cancer.